Autonomix Medical (AMIX) shares were up more than 10% in recent premarket activity Thursday after the medical device company said the US Patent and Trademark Office had granted it a patent for its proprietary catheter-based technology used to collect and process sensing data for real-time physiological monitoring.
The company said the broad applications for the technology include heart mapping, arterial mapping, parenchymal monitoring, central nervous system monitoring, and implant, robotic and wearable precision applications.
Autonomix Medical said it expects to file an investigational device exemption with the US Food and Drug Administration.
The company also said it aims to begin US clinical trials this year in support of a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the US to treat pancreatic cancer pain.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。